NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
Eli Lilly and Company
Alaunos Therapeutics
Regeneron Pharmaceuticals
University of California, San Francisco
Weill Medical College of Cornell University
University of California, San Francisco
National Cancer Institute (NCI)
Children's Hospital Medical Center, Cincinnati